UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12Aaron Lee, Adnan Tufail, Martin McKibbin et al.|British Journal of Ophthalmology|2015Cited by 60
The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomesThomas Butt, Adnan Tufail, Aaron Lee et al.|BMJ Open|2015Cited by 23
Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes dataAaron Lee, Adnan Tufail, Thomas Butt et al.|British Journal of Ophthalmology|2017Cited by 14
Ranibizumab Therapy for Neovascular AMD in eyes with good vision (>6/12): visual outcomes and cost-effectiveness based on real world outcomes of 92,976 treatment episodesAdnan Tufail, Thomas Butt, Aaron Lee et al.|Investigative Ophthalmology & Visual Science|2015Cited by 0